FREMONT, Calif., Oct. 13 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(Nasdaq: PDLI) today announced the filing with the U.S. Securities and
Exchange Commission of Prospectus Supplement No. 1 to the Prospectus
contained in Post-Effective Amendment No. 2 to Form S-3 Registration
Statement relating to the 2.00% Convertible Senior Notes due 2012 in an
aggregate amount of $250.0 million. The offering of the notes was completed
in February 2005 pursuant to Rule 144A under the Securities Act of 1933, as
amended.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life- threatening illnesses. The company currently markets and sells a
portfolio of leading products in the acute-care hospital setting in the
United States and Canada and generates royalties through licensing
agreements with top-tier biotechnology and pharmaceutical companies based
on its pioneering antibody humanization technology. Currently, PDL's
diverse product pipeline includes investigational compounds in Phase 2 or
Phase 3 clinical development for inflammation and autoimmune diseases,
cardiovascular disorders and cancer. The company's research platform is
focused on the discovery and development of antibodies for the treatment of
cancer and autoimmune diseases. For more information, please see PDL's
website at http://www.pdl.com .
NOTE: PDL BioPharma and the PDL BioPharma logo are considered
trademarks of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com/
CONTACT:
Ami Knoefler, Corporate and Investor
Relations of PDL BioPharma, +1-510-284-8851, or
ami.knoefler@pdl.com
|
